Takeaways from ACMG 2012

The addition of the word “Genomics” to the American College of Genetics tagline is the clearest indicator of the activity we’ve seen in the diagnostic industry over the past year. If you’re not already employing or planning to employ next-generation sequencing in your clinical genetics lab, you stand to become irrelevant. The meeting was absolutely dominated ...

Continue Reading ...

Engaging the European Patent Community

Many of you know that GenomeQuest provides patent experts a market-leading research platform on biological sequences.  While we're very much a standard in large pharma/AG globally and biotech in the US, we've recently begun a major initiative to engage and expand our biotech community in the EU. In support of this initiative, I had the ...

Continue Reading ...

Treatments not Terabytes

The genomics industry has a PR problem and it’s largely a self-made one. When I read articles about the latest in physics research and The Large Hadron Collider at CERN, I read about how the collider will be used to find new particles that will fundamentally alter our understanding of the universe. The fact that ...

Continue Reading ...

CMDx — A Killer App for NGS

Last Wednesday, I woke up to a NYT article by Andrew Pollack on the "Deluge of Data" that seemingly haunts the genomics field.  The very next morning, I awoke to a folder full of applications for the GenomeQuest NGS software grant for consolidated gene-panel tests. Talk about night and day! While it's reasonable to question ...

Continue Reading ...

PM Conference (HMS) and Executive Workshop Review

Last week, I attended the Personalized Medicine Conference (PMC) at HMS, moderated by Dr. Raju Kucherlapati.  It was, yet again, outstanding in terms of quality of content, presenters, and networking.  Immediately afterwards, GenomeQuest and NGS Leaders hosted over 30 moderators and Dx executives at a post-conference workshop to immediately exercise and apply ...

Continue Reading ...

Top 7 Thoughts Heard at ICHG

Last week, I attended the International Congress of Human Genetics conference in Montreal. Overall, it provided a wonderful and thorough update on the state of genetic research, practice, and plans – bravo to the show organizers and all presenters! Below are the top seven thoughts I heard in my sessions and around the ...

Continue Reading ...

Personalized Medicine for Cancer on CBS Evening News

On the 40th anniversary of the National Cancer Act, the American Association of Cancer Research (AACR) this week issued its first "Cancer Progress Report". It's an outstanding, 84-page narrative that outlines the progress in our understanding/treatment of cancer and the criticality of genomics in transforming patient care going forward. You can download the full report here ...

Continue Reading ...

Leader in the Development of the Electronic Health Record is Integrating Whole Genome Analysis

The pioneer in the Electronic Health Record is the U.S. Department of Veterans Administration, with the development of the the Veterans Health Information Systems and Technology Architecture (VistA). They are again on the forefront of the design and development of a new VistA Electronic Health Record (EHR), using an eclectic open source model involving academia, the ...

Continue Reading ...

Clinical sequencing to reach $3.6B?

The recent Macquarie report on clinical sequencing named our diagnostic decision support product, GQ-Dx, the technology leader in informatics and interpretation of clinical sequencing. In that report, they described a scenario where in as little as three years the clinical sequencing market could reach $3.6B. Believe it? GQ-Dx is our response to an overflowing demand by ...

Continue Reading ...

NGS for Diagnostics Could Soon Surpass $3B in U.S., GenomeQuest Named “Technology Leader” — Macquarie Capital

In its third in a series of industry reports on the sequencing landscape, equity research specialist Macquarie Capital focused on the dynamics and opportunities in the clinical space. Included in the July 8, 2011 report: In as soon as three years, NGS testing could reach $3.6B in the U.S. (others have noted that MDx is the fasting ...

Continue Reading ...